SSR-180,711 explained

SSR180711 is a drug that acts as a potent and selective partial agonist for the α7 subtype of neural nicotinic acetylcholine receptors.^{[1] [2]} In animal studies, it shows nootropic effects and may be useful in the treatment of schizophrenia.^{[3] [4]}

Notes and References

1. Pichat P, Bergis OE, Terranova JP, Urani A, Duarte C, Santucci V, Gueudet C, Voltz C, Steinberg R, Stemmelin J, Oury-Donat F, Avenet P, Griebel G, Scatton B . 6 . SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia . Neuropsychopharmacology . 32 . 1 . 17–34 . January 2007 . 16936709 . 10.1038/sj.npp.1301188 . free .
2. Biton B, Bergis OE, Galli F, Nedelec A, Lochead AW, Jegham S, Godet D, Lanneau C, Santamaria R, Chesney F, Léonardon J, Granger P, Debono MW, Bohme GA, Sgard F, Besnard F, Graham D, Coste A, Oblin A, Curet O, Vigé X, Voltz C, Rouquier L, Souilhac J, Santucci V, Gueudet C, Françon D, Steinberg R, Griebel G, Oury-Donat F, George P, Avenet P, Scatton B . 6 . SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile . Neuropsychopharmacology . 32 . 1 . 1–16 . January 2007 . 17019409 . 10.1038/sj.npp.1301189 . free .
3. Hashimoto K, Ishima T, Fujita Y, Matsuo M, Kobashi T, Takahagi M, Tsukada H, Iyo M . 6 . Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711 . Biological Psychiatry . 63 . 1 . 92–7 . January 2008 . 17601496 . 10.1016/j.biopsych.2007.04.034 . free .
4. Barak S, Arad M, De Levie A, Black MD, Griebel G, Weiner I . Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia . Neuropsychopharmacology . 34 . 7 . 1753–63 . June 2009 . 19158670 . 10.1038/npp.2008.232 . 10.1.1.470.1879 . 827363 .